AstraZeneca_NNP Code_NNP of_IN Conduct_NNP 157_CD ASTRAZENECA_NNP CODE_NNP OF_IN CONDUCT_NNP INTRODUCTION_NNP situations_NNS should_MD be_VB sought_VBN from_IN management_NN ._.
AstraZeneca_NNP funds_NNS will_MD not_RB be_VB used_VBN in_IN We_PRP are_VBP committed_VBN to_TO dealing_VBG with_IN all_DT our_PRP$ In_IN addition_NN ,_, Legal_NNP Department_NNP and_CC Group_NNP payments_NNS ,_, direct_JJ or_CC indirect_JJ ,_, to_TO government_NN stakeholders_NNS with_IN the_DT highest_JJS ethical_JJ standards_NNS ,_, Internal_NNP Audit_NNP are_VBP available_JJ on_IN a_DT confidential_JJ officials_NNS ,_, people_NNS participating_VBG in_IN government_NN integrity_NN and_CC as_IN responsible_JJ corporate_JJ citizens_NNS ._.
basis_NN as_IN independent_JJ sources_NNS of_IN advice_NN ._.
bodies_NNS ,_, employees_NNS of_IN state_NN organizations_NNS or_CC The_DT trust_NN and_CC confidence_NN of_IN all_DT our_PRP$ stakeholders_NNS ,_, representatives_NNS of_IN political_JJ parties_NNS ,_, for_IN unlawful_JJ together_RB with_IN our_PRP$ reputation_NN ,_, are_VBP among_IN the_DT It_PRP is_VBZ the_DT responsibility_NN of_IN each_DT employee_NN to_TO or_CC improper_JJ purposes_NNS ._.
most_RBS valuable_JJ assets_NNS of_IN the_DT Group_NNP ._.
Along_IN with_IN report_NN promptly_RB any_DT violations_NNS of_IN the_DT Code_NNP our_PRP$ commitment_NN to_TO competitiveness_NN and_CC of_IN Conduct_NNP of_IN which_WDT they_PRP become_VBP aware_JJ ._.
Equal_NNP opportunities_NNS performance_NN ,_, we_PRP will_MD continue_VB to_TO be_VB led_VBN by_IN AstraZeneca_NNP assures_VBZ individual_JJ employees_NNS All_DT employees_NNS shall_MD be_VB treated_VBN with_IN equal_JJ our_PRP$ values_NNS to_TO achieve_VB sustainable_JJ success_NN ._.
who_WP raise_VBP issues_NNS that_IN they_PRP will_MD be_VB protected_VBN respect_NN and_CC dignity_NN and_CC shall_MD be_VB provided_VBN from_IN any_DT adverse_JJ impact_NN on_IN their_PRP$ employment_NN with_IN equality_NN of_IN opportunity_NN to_TO develop_VB Every_DT AstraZeneca_NNP employee_NN is_VBZ required_VBN to_TO as_IN a_DT result_NN ._.
AstraZeneca_NNP actively_RB encourages_VBZ themselves_PRP and_CC their_PRP$ careers_NNS ._.
make_VB a_DT personal_JJ commitment_NN to_TO follow_VB the_DT employees_NNS to_TO raise_VB issues_NNS of_IN concern_NN ._.
Companys_NNP Code_NNP of_IN Conduct_NNP ,_, as_RB well_RB as_IN the_DT AstraZeneca_NNP is_VBZ striving_VBG to_TO achieve_VB diversity_NN detailed_JJ standards_NNS issued_VBN in_IN support_NN of_IN it_PRP ,_, and_CC STANDARDS_NNPS OF_IN CONDUCT_NNP at_IN all_DT levels_NNS of_IN the_DT organization_NN and_CC values_VBZ the_DT uphold_VB our_PRP$ commitment_NN to_TO our_PRP$ values_NNS ,_, integrity_NN Business_NN practices_NNS individuality_NN ,_, diversity_NN and_CC creative_JJ potential_NN and_CC corporate_JJ responsibility_NN ._.
AstraZeneca_NNP Companies_NNS ,_, and_CC their_PRP$ employees_NNS ,_, that_IN every_DT employee_NN brings_VBZ to_TO its_PRP$ business_NN must_MD comply_VB with_IN the_DT laws_NNS of_IN all_DT countries_NNS and_CC supports_VBZ the_DT continuous_JJ development_NN We_PRP are_VBP all_DT privileged_JJ to_TO work_VB for_IN one_CD of_IN the_DT best_JJS in_IN which_WDT they_PRP operate_VBP ,_, with_IN appropriate_JJ of_IN their_PRP$ skills_NNS and_CC abilities_NNS ._.
companies_NNS in_IN the_DT world_NN and_CC must_MD ensure_VB we_PRP international_JJ and_CC national_JJ industry_NN codes_NNS of_IN leave_VBP a_DT lasting_JJ legacy_NN ._.
Nothing_NN not_RB the_DT need_NN practice_NN and_CC with_IN the_DT high_JJ ethical_JJ standards_NNS Judgements_NNP about_IN people_NNS for_IN the_DT purpose_NN to_TO meet_VB targets_NNS ,_, or_CC direct_JJ orders_NNS from_IN a_DT specified_VBN by_IN AstraZeneca_NNP ._.
of_IN recruitment_NN ,_, development_NN or_CC promotion_NN superior_JJ should_MD ever_RB compromise_VB our_PRP$ shall_MD be_VB made_VBN solely_RB on_IN the_DT basis_NN of_IN a_DT persons_NNS commitment_NN to_TO honesty_NN and_CC integrity_NN ._.
It_PRP is_VBZ the_DT responsibility_NN of_IN all_DT employees_NNS to_TO ability_NN and_CC potential_NN in_IN relation_NN to_TO the_DT needs_NNS of_IN ensure_VB ,_, by_IN taking_VBG advice_NN where_WRB appropriate_JJ ,_, the_DT job_NN and_CC shall_MD only_RB take_VB account_NN of_IN matters_NNS SIR_NNP TOM_NNP MCKILLOP_NNP that_IN they_PRP are_VBP fully_RB aware_JJ of_IN all_DT relevant_JJ laws_NNS ,_, relevant_JJ to_TO the_DT performance_NN of_IN that_DT job_NN ._.
Overall_RB ,_, Chief_NNP Executive_NNP regulations_NNS ,_, practices_NNS and_CC codes_NNS of_IN practice_NN ,_, success_NN and_CC advancement_NN within_IN AstraZeneca_NNP July_NNP 2003_CD particularly_RB as_IN they_PRP relate_VBP to_TO their_PRP$ job_NN ._.
shall_MD depend_VB solely_RB on_IN personal_JJ ability_NN ,_, behavior_NN and_CC work_NN performance_NN ._.
POLICY_NNP Employees_NNS should_MD ensure_VB that_IN ,_, within_IN their_PRP$ AstraZeneca_NNP requires_VBZ its_PRP$ companies_NNS ,_, and_CC their_PRP$ sphere_NN of_IN business_NN activity_NN ,_, AstraZeneca_NNP In_IN some_DT countries_NNS these_DT principles_NNS may_MD employees_NNS ,_, to_TO observe_VB the_DT highest_JJS standards_NNS Companies_NNS carry_VBP out_RP their_PRP$ contractual_JJ be_VB modified_VBN by_IN national_JJ legal_JJ requirements_NNS of_IN integrity_NN and_CC honesty_NN and_CC act_NN with_IN due_JJ skill_NN ,_, obligations_NNS in_IN a_DT proper_JJ and_CC timely_JJ manner_NN for_IN affirmative_JJ action_NN ._.
care_NN ,_, diligence_NN and_CC fairness_NN in_IN the_DT conduct_NN and_CC are_VBP not_RB in_IN breach_NN of_IN contract_NN ._.
To_TO this_DT end_NN all_DT AstraZeneca_NNP Personal_NNP harassment_NN Companies_NNS ,_, and_CC their_PRP$ employees_NNS ,_, are_VBP required_VBN Business_NN practice_NN ,_, and_CC what_WP amounts_NNS Personal_JJ harassment_NN ,_, such_JJ as_IN verbal_JJ abuse_NN to_TO comply_VB with_IN the_DT laws_NNS of_IN all_DT countries_NNS in_IN to_TO improper_JJ conduct_NN ,_, varies_VBZ from_IN country_NN or_CC sexual_JJ harassment_NN ,_, of_IN any_DT employee_NN which_WDT they_PRP operate_VBP and_CC with_IN the_DT high_JJ ethical_JJ to_TO country_NN and_CC from_IN industry_NN to_TO industry_NN ._.
All_DT of_IN AstraZeneca_NNP ,_, its_PRP$ suppliers_NNS or_CC customers_NNS standards_NNS detailed_VBN by_IN AstraZeneca_NNP in_IN support_NN employees_NNS will_MD comply_VB with_IN a_DT the_DT high_JJ ethical_JJ is_VBZ unacceptable_JJ in_IN any_DT form_NN whatsoever_RB ._.
standards_NNS specified_VBN by_IN AstraZeneca_NNP b_NN any_DT published_VBN overall_JJ AstraZeneca_NNP Code_NNP relating_VBG Any_DT person_NN who_WP believes_VBZ they_PRP have_VBP been_VBN COMPLIANCE_NNP to_TO business_NN practices_NNS and_CC c_NN any_DT international_JJ personally_RB harassed_VBN should_MD report_VB the_DT incident_NN It_PRP is_VBZ the_DT responsibility_NN of_IN management_NN to_TO ensure_VB and_CC national_JJ codes_NNS of_IN practice_NN applicable_JJ to_TO and_CC circumstances_NNS to_TO their_PRP$ immediate_JJ manager_NN that_IN the_DT AstraZeneca_NNP Code_NNP of_IN Conduct_NNP and_CC the_DT conduct_NN of_IN business_NN in_IN each_DT environment_NN ._.
or_CC HR_NNP manager_NN or_CC other_JJ senior_JJ manager_NN who_WP standards_NNS are_VBP communicated_VBN ,_, understood_VBN will_MD arrange_VB for_IN it_PRP to_TO be_VB investigated_VBN impartially_RB and_CC acted_VBD upon_IN ._.
They_PRP are_VBP required_VBN to_TO positively_RB Gifts_NNP ,_, entertainment_NN and_CC personal_JJ favors_NNS may_MD and_CC confidentially_RB ._.
promote_VB them_PRP by_IN personal_JJ example_NN and_CC are_VBP only_RB be_VB offered_VBN to_TO a_DT third_JJ party_NN if_IN modest_JJ in_IN not_RB entitled_VBN to_TO permit_VB any_DT exceptions_NNS to_TO the_DT value_NN and_CC if_IN they_PRP are_VBP consistent_JJ with_IN customary_JJ AstraZeneca_NNP is_VBZ fully_RB supportive_JJ of_IN the_DT principles_NNS required_VBN behavior_NN ._.
No_DT gifts_NNS ,_, entertainment_NN or_CC set_VBN forth_RB in_IN the_DT UN_NNP Declaration_NNP of_IN Human_NNP personal_JJ favor_NN may_MD be_VB offered_VBN in_IN contravention_NN Rights_NNS ._.
These_DT include_VBP freedom_NN from_IN torture_VB All_DT employees_NNS should_MD familiarise_VB themselves_PRP of_IN any_DT applicable_JJ law_NN or_CC code_NN of_IN practice_NN ._.
and_CC arbitrary_JJ arrest_NN ,_, the_DT right_NN to_TO a_DT fair_JJ trial_NN and_CC with_IN the_DT Code_NNP of_IN Conduct_NNP and_CC must_MD comply_VB equality_NN before_IN the_DT law_NN ._.
Failure_NN to_TO act_VB in_IN compliance_NN with_IN the_DT No_NNP employee_NN should_MD seek_VB or_CC accept_VB a_DT gift_NN ,_, Code_NNP will_MD result_VB in_IN appropriate_JJ disciplinary_JJ entertainment_NN or_CC personal_JJ favor_NN which_WDT Political_NNP contributions_NNS action_NN against_IN both_DT the_DT employee_NN committing_VBG might_MD reasonably_RB be_VB believed_VBN to_TO have_VB any_DT Any_DT political_JJ contributions_NNS by_IN AstraZeneca_NNP the_DT breach_NN and_CC others_NNS who_WP condone_VBP it_PRP ._.
An_DT offer_NN of_IN Companies_NNS must_MD be_VB lawful_JJ and_CC approved_VBD entertainment_NN should_MD not_RB be_VB accepted_VBN unless_IN under_IN procedures_NNS laid_VBN down_RP by_IN the_DT board_NN or_CC The_DT Standards_NNPS set_VBD out_RP in_IN the_DT Code_NNP are_VBP general_JJ the_DT offer_NN is_VBZ within_IN the_DT bounds_NNS of_IN accepted_VBN governing_VBG body_NN of_IN the_DT Company_NN concerned_VBN ._.
and_CC do_VB not_RB address_VB each_DT and_CC every_DT situation_NN business_NN hospitality_NN ._.
Gifts_NNS which_WDT do_VBP not_RB meet_VB that_DT may_MD confront_VB employees_NNS in_IN markets_NNS around_IN the_DT above_JJ criteria_NNS should_MD be_VB reported_VBN to_TO Approval_NNP should_MD not_RB be_VB given_VBN to_TO any_DT political_JJ the_DT world_NN ._.
In_IN appropriate_JJ cases_NNS ,_, guidance_NN management_NN who_WP shall_MD determine_VB how_WRB they_PRP contributions_NNS by_IN AstraZeneca_NNP Companies_NNS on_IN the_DT application_NN of_IN the_DT Code_NNP to_TO particular_JJ shall_MD be_VB dealt_VBN with_IN ._.
which_WDT ,_, by_IN their_PRP$ scale_NN or_CC affiliation_NN ,_, might_MD AstraZeneca_NNP Annual_JJ Report_NNP and_CC 158_CD Form_NN 20-F_JJ Information_NN 2005_CD ASTRAZENECA_NNP CODE_NNP OF_IN CONDUCT_NNP CONTINUED_VBD be_VB seen_VBN as_IN excessive_JJ or_CC inappropriate_JJ ._.
Property_NN and_CC resources_NNS Records_NNPS ,_, disclosures_NNS and_CC communications_NNS AstraZenecas_NNP accounting_NN procedures_NNS require_VBP AstraZeneca_NNP resources_NNS should_MD be_VB kept_VBN AstraZeneca_NNP PLC_NNP and_CC all_DT AstraZeneca_NNP any_DT political_JJ contribution_NN to_TO be_VB reported_VBN securely_RB and_CC should_MD only_RB be_VB used_VBN for_IN the_DT Companies_NNS and_CC their_PRP$ employees_NNS are_VBP to_TO AstraZeneca_NNP headquarters_NN as_IN part_NN of_IN the_DT proper_JJ advancement_NN of_IN its_PRP$ business_NN and_CC required_VBN to_TO keep_VB proper_JJ accounting_NN and_CC annual_JJ consolidation_NN of_IN results_NNS ._.
other_JJ records_NNS which_WDT give_VBP a_DT true_JJ and_CC fair_JJ view_NN of_IN the_DT financial_JJ position_NN ,_, results_NNS of_IN Conflicts_NNS of_IN interest_NN Individuals_NNS expending_VBG AstraZeneca_NNP resources_NNS operations_NNS ,_, transactions_NNS ,_, assets_NNS and_CC Employees_NNS dealing_VBG with_IN AstraZenecas_NNP should_MD recognize_VB that_IN they_PRP owe_VBP a_DT duty_NN of_IN care_NN liabilities_NNS so_RB as_IN to_TO enable_VB the_DT Company_NN business_NN must_MD act_VB in_IN the_DT best_JJS interests_NNS to_TO the_DT shareholders_NNS of_IN AstraZeneca_NNP ,_, who_WP to_TO make_VB full_JJ ,_, fair_JJ ,_, accurate_JJ ,_, timely_JJ and_CC of_IN AstraZeneca_NNP and_CC must_MD disregard_VB any_DT are_VBP its_PRP$ ultimate_JJ owners_NNS ._.
Commitments_NNS and_CC understandable_JJ disclosures_NNS in_IN all_DT reports_NNS personal_JJ preference_NN or_CC advantage_NN ._.
expenditure_NN should_MD only_RB be_VB such_JJ as_IN could_MD it_PRP is_VBZ required_VBN to_TO publish_VB ,_, file_VB or_CC submit_VB be_VB justified_VBN to_TO shareholders_NNS if_IN the_DT facts_NNS were_VBD to_TO shareholders_NNS and_CC regulators_NNS and_CC in_IN all_DT Employees_NNS should_MD avoid_VB entering_VBG into_IN situations_NNS known_VBN ._.
This_DT includes_VBZ any_DT expenses_NNS claimed_VBD other_JJ communications_NNS which_WDT it_PRP publishes_VBZ ._.
in_IN which_WDT their_PRP$ personal_JJ ,_, family_NN or_CC financial_JJ and_CC purchases_NNS made_VBN for_IN which_WDT reimbursement_NN interests_NNS may_MD conflict_VB with_IN those_DT of_IN AstraZeneca_NNP ._.
All_DT accounting_NN and_CC other_JJ records_NNS will_MD be_VB Where_WRB any_DT potential_JJ conflict_NN of_IN interest_NN may_MD maintained_VBD in_IN a_DT manner_NN that_WDT describes_VBZ and_CC arise_VB ,_, the_DT employee_NN shall_MD declare_VB that_IN interest_NN AstraZeneca_NNP resources_NNS include_VBP not_RB only_RB documents_NNS accurately_RB the_DT Companys_NNPS true_JJ and_CC seek_VB advice_NN from_IN senior_JJ management_NN ._.
tangible_JJ assets_NNS such_JJ as_IN materials_NNS ,_, equipment_NN financial_JJ position_NN and_CC results_NNS of_IN operations_NNS and_CC and_CC cash_NN ,_, but_CC also_RB intangible_JJ assets_NNS such_PDT the_DT true_JJ nature_NN of_IN its_PRP$ business_NN transactions_NNS ,_, Examples_NNS of_IN conflict_NN to_TO be_VB declared_VBN and_CC as_IN computer_NN systems_NNS ,_, trade_NN secrets_NNS and_CC assets_NNS and_CC liabilities_NNS ._.
Accounting_NN records_NNS will_MD resolved_VBN include_VBP :_: confidential_JJ information_NN ._.
Employees_NNS should_MD be_VB kept_VBN in_IN accordance_NN with_IN AstraZeneca_NNP policies_NNS ,_, observe_VBP global_JJ and_CC local_JJ guidelines_NNS relevant_JJ accounting_NN standards_NNS and_CC appropriate_JJ Having_VBG a_DT family_NN interest_NN in_IN a_DT transaction_NN with_IN concerning_VBG the_DT classifying_VBG and_CC handling_VBG of_IN generally_RB accepted_VBN accounting_NN principles_NNS ._.
AstraZeneca_NNP or_CC one_CD of_IN its_PRP$ subsidiaries_NNS the_DT documents_NNS and_CC electronic_JJ data_NNS ._.
The_DT storage_NN Company_NN or_CC any_DT supplier_NN or_CC customer_NN ._.
of_IN personal_JJ data_NNS in_IN an_DT electronic_JJ medium_NN may_MD Employees_NNS must_MD ensure_VB that_IN all_DT reports_NNS Hiring_NNP of_IN a_DT family_NN member_NN in_IN any_DT capacity_NN ._.
be_VB governed_VBN by_IN laws_NNS with_IN which_WDT relevant_JJ published_VBN ,_, filed_VBN or_CC submitted_VBN to_TO shareholders_NNS Having_VBG an_DT interest_NN ,_, directly_RB or_CC through_IN employees_NNS should_MD familiarise_VB themselves_PRP and_CC regulators_NNS and_CC all_DT other_JJ communications_NNS family_NN ,_, in_IN a_DT competitor_NN ,_, supplier_NN or_CC customer_NN and_CC comply_VB ._.
which_WDT are_VBP published_VBN by_IN the_DT Company_NN are_VBP full_JJ ,_, of_IN the_DT Company_NN ._.
fair_JJ ,_, accurate_JJ ,_, timely_JJ and_CC understandable_JJ :_: they_PRP Having_VBG an_DT interest_NN ,_, directly_RB or_CC through_IN Information_NNP generated_VBD within_IN AstraZeneca_NNP ,_, must_MD not_RB mislead_VB the_DT reader_NN in_IN any_DT way_NN or_CC omit_VB family_NN ,_, in_IN an_DT organization_NN that_WDT has_VBZ ,_, or_CC seeks_VBZ including_VBG research_NN and_CC development_NN and_CC anything_NN necessary_JJ to_TO make_VB them_PRP full_JJ ,_, fair_JJ and_CC to_TO do_VB business_NN with_IN the_DT Company_NN ._.
manufacturing_VBG data_NNS ,_, costs_NNS ,_, prices_NNS ,_, sales_NNS ,_, profits_NNS ,_, accurate_JJ ._.
The_DT Chief_NNP Executive_NNP and_CC the_DT Acquiring_VBG an_DT interest_NN in_IN property_NN such_JJ markets_NNS ,_, customers_NNS and_CC methods_NNS of_IN doing_VBG Companys_NNP senior_JJ financial_JJ officers_NNS have_VBP as_IN real_JJ estate_NN ,_, patent_NN rights_NNS or_CC securities_NNS business_NN ,_, is_VBZ the_DT property_NN of_IN AstraZeneca_NNP and_CC a_DT particular_JJ responsibility_NN in_IN this_DT regard_NN ._.
where_WRB the_DT Company_NN has_VBZ ,_, or_CC might_MD have_VB ,_, must_MD not_RB ,_, unless_IN legally_RB required_VBN ,_, be_VB disclosed_VBN an_DT interest_NN ._.
outside_IN AstraZeneca_NNP without_IN proper_JJ authority_NN ._.
These_DT examples_NNS do_VBP not_RB extend_VB to_TO normal_JJ and_CC Policies_NNS ,_, delegated_VBN authorities_NNS proper_JJ financial_JJ investments_NNS in_IN publicly_RB quoted_VBN and_CC reserved_VBN powers_NNS companies_NNS ._.
AstraZeneca_NNP employees_NNS are_VBP expected_VBN to_TO make_VB themselves_PRP aware_JJ of_IN and_CC comply_VB Insider_NNP information_NN with_IN the_DT letter_NN and_CC spirit_NN of_IN all_DT AstraZeneca_NNP Employees_NNS must_MD not_RB use_VB confidential_JJ policies_NNS and_CC with_IN the_DT reserved_VBN powers_NNS and_CC information_NN obtained_VBN through_IN their_PRP$ delegated_JJ authorities_NNS established_VBN by_IN the_DT employment_NN for_IN personal_JJ gain_NN ._.
Copies_NNS of_IN these_DT are_VBP available_JJ on_IN the_DT Companys_NNP intranet_NN site_NN s._VB It_PRP is_VBZ AstraZeneca_NNP policy_NN ,_, and_CC in_IN certain_JJ countries_NNS a_DT legal_JJ requirement_NN carrying_VBG criminal_JJ sanctions_NNS ,_, The_DT freedoms_NNS which_WDT individuals_NNS have_VBP to_TO carry_VB that_IN employees_NNS in_IN possession_NN of_IN confidential_JJ out_IN their_PRP$ jobs_NNS must_MD be_VB exercised_VBN within_IN both_DT price_NN sensitive_JJ information_NN in_IN relation_NN to_TO the_DT letter_NN and_CC spirit_NN of_IN AstraZeneca_NNP policies_NNS securities_NNS do_VBP not_RB make_VB use_NN of_IN such_JJ information_NN and_CC procedures_NNS ,_, reserved_VBN powers_NNS and_CC to_TO deal_VB in_IN securities_NNS of_IN AstraZeneca_NNP or_CC provide_VB delegated_JJ authorities_NNS ._.
These_DT are_VBP designed_VBN such_JJ information_NN to_TO third_JJ parties_NNS for_IN that_DT to_TO empower_VB people_NNS to_TO carry_VB out_RP their_PRP$ purpose_NN ._.
The_DT same_JJ considerations_NNS apply_VBP responsibilities_NNS within_IN a_DT necessary_JJ framework_NN in_IN relation_NN to_TO confidential_JJ price_NN sensitive_JJ of_IN corporate_JJ control_NN and_CC legal_JJ responsibility_NN information_NN relating_VBG to_TO other_JJ companies_NNS and_CC but_CC are_VBP not_RB so_RB voluminous_JJ as_IN to_TO prescribe_VB dealing_VBG in_IN their_PRP$ securities_NNS ._.
appropriate_JJ action_NN in_IN every_DT circumstance_NN ._.
